NCT01497769已完成1 期
A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intradermal Route in Healthy BCG-vaccinated Adult Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Safety of MVA85A vaccination by the aerosol inhaled route
研究概览
简要总结
This is a phase I trial to compare the safety and immunogenicity of candidate TB vaccine MVA85A administered by the aerosol inhaled route and the intradermal route in healthy BCG-vaccinated adult subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults aged 18-50 years
- •Resident in or near Oxford for the duration of the trial period
- •No relevant findings in medical history or on physical examination
- •Confirmation of prior vaccination with BCG not less than 6 months prior to projected trial vaccination date (by visible BCG scar on examination or written documentation)
- •Allow the Investigators to discuss the individual's medical history with their GP
- •Use effective contraception for the duration of the trial period (females only)
- •Refrain from blood donation during the trial
- •Give written informed consent
- •Allow the Investigator to register subject details with a confidential database to prevent concurrent entry into clinical trials
- •Able and willing (in the Investigator's opinion) to comply with all the trial requirements
排除标准
- •Any respiratory disease, including asthma
- •Current smoker
- •Clinically significant abnormality on screening chest x rays
- •Clinically significant abnormality of pulmonary function tests
- •Any nasal, pharyngeal, or laryngeal finding which precludes bronchoscopy
- •Current use of any medication taken through the nasal or inhaled route including cocaine or other recreational drugs
- •Laboratory evidence at screening of latent M.tb infection as indicated by a positive ELISPOT response to ESAT6 or CFP10 antigens
- •Clinical, radiological, or laboratory evidence of current active TB disease
- •Previous vaccination with candidate vaccine MVA85A or candidate vaccine FP85A or any other recombinant MVA vaccine
- •Clinically significant history of skin disorder, allergy, immunodeficiency (including HIV), cancer (except BCC or CIS), cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, neurological illness, psychiatric disorder, drug or alcohol abuse
- •History of serious psychiatric condition
- •Concurrent oral or systemic steroid medication or the concurrent use of other immunosuppressive agents
- •History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine, sedative drugs, or any local or general anaesthetic agents
- •Any abnormality of screening blood or urine tests that is deemed to be clinically significant or that may compromise the safety of the subject in the trial
- •Positive HBsAg, HCV or HIV antibodies
- •Female currently lactating, confirmed pregnancy or intention to become pregnant during trial period
- •Use of an investigational medicinal product or non-registered drug, live vaccine, or medical device other than the trial vaccine for 30 days prior to dosing with the trial vaccine, or planned use during the trial period
- •Administration of immunoglobulins and/or any blood products within the three months preceding the planned trial vaccination date
- •Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may either put the subject at risk or may influence the result of the trial or may affect the subject's ability to participate in the trial
结局指标
主要结局
Safety of MVA85A vaccination by the aerosol inhaled route
时间窗: 24 weeks following vaccination
To evaluate the safety in healthy BCG-vaccinated subjects of MVA85A vaccination by the aerosol inhaled route by actively and passively collecting data on adverse events
次要结局
- Immunogenicity of MVA85A vaccination by the aerosol inhaled route compared with the intradermal route(24 weeks following vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIVTuberculosisNCT00731471University of Oxford24
已完成
2 期
A Study of MVA85A in Healthy Children and InfantsTuberculosisNCT00679159University of Oxford168
已完成
1 期
A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85ATuberculosisNCT00653770University of Oxford31
已完成
1 期
A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive VolunteersTuberculosisNCT00929396Statens Serum Institut20
已完成
1 期
A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis(TB) Subunit VaccineTuberculosisNCT01003093Statens Serum Institut36